Inhibikase Therapeutics (IKT) Selling, General & Administrative (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Selling, General & Administrative of $7.66 million for Q2 2026, up 29.4% from $5.92 million a year earlier and up 3.8% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Selling, General & Administrative (2020 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Inhibikase Therapeutics' Selling, General & Administrative came in at $27.42 million, up 47.9% year-over-year; for FY2025, it came in at $23.56 million, up 107.0% from FY2024.
- Selling, General & Administrative has increased for three consecutive years, with a five-year compound annual growth rate of 55.1% (FY2020 to FY2025).
- By year, Selling, General & Administrative came in at $11.38 million in FY2024 (+69.0%), $6.73 million in FY2023 (+8.3%), $6.22 million in FY2022 (-4.5%) and $6.51 million in FY2021 (+148.1%).
- The Q2 2026 figure ranks as the highest quarterly Selling, General & Administrative in data going back to Q1 2020.
- Year over year, Selling, General & Administrative has now increased in each of the last 14 quarters, with growth averaging 124.9% over the last eight quarters.
- The high point for year-over-year Selling, General & Administrative in five years was Q4 2024 (growth of 309.5%); the low point was Q4 2022 (a decline of 18.7%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $7.38 million (Q1 2026), $6.77 million (Q4 2025) and $5.61 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 3.13 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 6.29 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.09 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.89 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 5.11 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 1.68 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.64 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.28 Bn |
| 10 | Inhibikase Therapeutics | 281.11 Mn | -420.36 Mn | - | 7.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 7.23 Mn |
| Jun 30, 2026 | 7.66 Mn |
| Mar 31, 2026 | 7.38 Mn |
| Dec 31, 2025 | 6.77 Mn |
| Sep 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 5.92 Mn |
| Mar 31, 2025 | 5.25 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Sep 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 1.97 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.78 Mn |
| Mar 31, 2023 | 1.93 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 1.66 Mn |
| Mar 31, 2022 | 1.67 Mn |
| Dec 31, 2021 | 1.65 Mn |
API Access
Inhibikase Therapeutics Selling, General & Administrative API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "selling-general-and-administrative", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();